ArticleScientific reports2019
Effects of defined gut microbial ecosystem components on virulence determinants of Clostridioides difficile.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- Article
- Personalized prediction of glycemic responses to food in women with diet-treated gestational diabetes: the role of the gut microbiota.NPJ biofilms and microbiomes · 2025Article
- Host Immune Responses toTropical medicine and infectious disease · 2023Review
- Network analysis of toxin production in Clostridioides difficile identifies key metabolic dependencies.PLoS computational biology · 2023Article
- Synthetic microbial communities (SynComs) of the human gut: design, assembly, and applications.FEMS microbiology reviews · 2023Article
- Immunological consequences of microbiome-based therapeutics.Frontiers in immunology · 2022Review
- Bacteriotherapy for inflammatory bowel disease.Inflammation and regeneration · 2021Review
- 1DCurrent protocols in chemical biology · 2020Article
- Dilution as a Solution: Targeting Microbial Populations with a Simplified Dilution Strategy.mSphere · 2020Article
- Flexible Cobamide Metabolism inJournal of bacteriology · 2020Article
- Antibacterial Activity ofFrontiers in cellular and infection microbiology · 2019Article
- Review
- EnterohemorrhagicGut microbesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Many cases of Clostridioides difficile infection (CDI) are poorly responsive to standard antibiotic treatment strategies, and often patients suffer from recurrent infections characterized by severe diarrhea. Our group previously reported the successful cure of two patients with recurrent CDI using a standardized stool-derived microbial ecosystem therapeutic (MET-1). Using an in vitro model of the distal gut to support bacterial communities, we characterized the metabolite profiles of two defined microbial ecosystems derived from healthy donor stool (DEC58, and a subset community, MET-1), as well as an ecosystem representative of a dysbiotic state (ciprofloxacin-treated DEC58). The growth and virulence determinants of two C. difficile strains were then assessed in response to components derived from the ecosystems. CD186 (ribotype 027) and CD973 (ribotype 078) growth was decreased upon treatment with DEC58 metabolites compared to ciprofloxacin-treated DEC58 metabolites. Furthermore, CD186 TcdA and TcdB secretion was increased following treatment with ciprofloxacin-treated DEC58 spent medium compared to DEC58 spent medium alone. The net metabolic output of C. difficile was also modulated in response to spent media from defined microbial ecosystems, although several metabolite levels were divergent across the two strains examined. Further investigation of these antagonistic properties will guide the development of microbiota-based therapeutics for CDI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.